Oportuzumab monatox

DB05319InvestigationalProtein Based Therapies

VB4-845 is studied in the treatment of certain types of head and neck cancer. VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill... VB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor cell-associated target highly expressed on carcinoma cells of epithelial origin and a truncated portion of Pseudomonas exotoxin...

Mechanism: VB4-845 binds to EpCAM (a protein on the surface of epithelial cells and some types of cancer cells). Also called anti-EpCAM-Pseudomonas-exotoxin fusion protein and Proxinium. It targets and kills Ep-CAM-positive tumors by apoptosis.
Curator reviewed
Primary indication: Investigated for use/treatment in bladder cancer and head and neck cancer.Curator reviewed
Code names: VB4-845

Resolves to

Compound

UNII945CY7ZMI2CAS945228-48-8

Clinical / RWD

ATCL01FX16

Targets

P16422EPCAMP13639EEF2

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 11 drug categories

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Oportuzumab monatox, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account